2011
Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers
Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L. Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. Clinical Cancer Research 2011, 17: 2591-2601. PMID: 21248301, DOI: 10.1158/1078-0432.ccr-10-1045.Peer-Reviewed Original ResearchConceptsER- cancersPredictive valueBreast cancerP53 signatureWorse distant metastasis-free survivalDistant metastasis-free survivalER-negative breast cancerAdjuvant tamoxifen therapyDifferent molecular subsetsMetastasis-free survivalDifferent prognostic valueNegative breast cancerHigher chemotherapy sensitivityTamoxifen therapyFree survivalBetter prognosisER-positivePoor prognosisPrognostic valuePrognostic markerMolecular subsetsChemotherapy sensitivityMutation statusP53 mutationsMultivariate analysis
2009
Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers.
Pusztai L, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Symmans W, Andre F, de The H, Coutant C, Coutant C. Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers. Cancer Research 2009, 69: 6122-6122. DOI: 10.1158/0008-5472.sabcs-09-6122.Peer-Reviewed Original ResearchDistant metastasis-free survivalP53 signatureBreast cancerER- cancersPredictive valueWorse distant metastasis-free survivalSystemic adjuvant therapyER- breast cancerMetastasis-free survivalNegative breast cancerDifferent molecular subtypesP53 functional statusP53 gene mutationsGene expression-based predictorsP53 mutation statusAdjuvant tamoxifenAdjuvant therapyFree survivalBackgroundBreast cancerFunctional statusMolecular subtypesIndependent cohortNeoplastic diseaseChemotherapy sensitivityMutation status